Biotech Hot Stocks - NASDAQ:ABIO, NYSEAMEX:HEB, NASDAQ:ARNA, NYSEAMEX:CVM

Scottsdale, AZ -- (SBWIRE) -- 01/31/2013 -- ArcaBiopharmaInc (NASDAQ:ABIO), a biopharmaceutical company, reported an update on a planned, genetically-targeted clinical trial in atrial fibrillation of the Company’s lead developmental drug, Gencaro (bucindolol hydrochloride). The Company also declared that Medtronic, Inc., a leader in medical technologies to increase the treatment of chronic diseases, including cardiac rhythm disorders, has contracted a non-binding Letter of Intent of agreement to work together on the preliminary, Phase 2B portion of the proposed trial.

In the mid-day trading hours, ArcaBiopharma Inc (NASDAQ:ABIO) reported the gain of +31.81% to $0.900 with the total traded volume of 3.67 million shares. Stock price 52 weeks high was $1.15 and 52 weeks low price was $0.23.

For How Long ABIO’s Gloss will Attract Investors? Find out via this report

HemispherxBioPharma, Inc (NYSEAMEX:HEB) surged +4.66% to $0.317 in the mid-day with the total traded volume of 3.53 million shares. Its fifty two week range was $0.23-$1.10. The total market capitalization remained $47.81million.

HEB is ahead its 52 week low with 0.82% and its last month price volatility remained 10.47%. Its beta coefficient was 1.24. HEB has insider ownership of 0.98% with its institutional ownership remained 4.85%. Company’s current year earnings per share grew with 32.10% while the five year EPS growth rate was +12.65%.

Will HEB Continue To Move Higher? Find Out Here

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) moved up +3.46% to $8.38 in the mid-day trading hours and its total traded volume was 3.93 million shares. ARNA has outstanding shares of $217.29 million with the total market cap of 1.82 billion and its beta value stands at 0.24 times. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs

CEL-SCI Corporation (NYSEAMEX:CVM) jumped +3.14% to $0.282 in the mid-day trading session with the total traded volume of 3.67 million shares more than the average volume of 1.10 million. CVM has market cap of 77.18 million. Stock price 52 weeks high was $0.65 and 52 weeks low price was $0.26.

Why Should Investors Buy CVM After The Recent Gain? Just Go Here and Find Out

About Universal Penny Stocks
universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.

We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.